For the quarter ended June 2025, Gilead Sciences (GILD) reported revenue of $7.08 billion, up 1.8% over the same period last year. EPS came in at $2.01, compared to $2.01 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $6.95 billion, representing a surprise of +1.95%. The company delivered an EPS surprise of +3.08%, with the consensus EPS estimate being $1.95.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Gilead performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Product Sales- Veklury- U.S.: $51 million versus the three-analyst average estimate of $69.13 million. The reported number represents a year-over-year change of -32.9%.
- Product Sales- Total HIV- U.S.: $4.1 billion compared to the $3.95 billion average estimate based on three analysts. The reported number represents a change of +7.2% year over year.
- Product Sales- Liver Disease- Sofosbuvir / Velpatasvir- U.S.: $184 million versus $225.96 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -31.1% change.
- Product Sales- HIV- Symtuza-Revenue share- U.S.: $88 million versus $117.66 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -32.8% change.
- Revenues- Royalty contract and other revenues: $27 million compared to the $38.09 million average estimate based on seven analysts. The reported number represents a change of -34.2% year over year.
- Total product sales- Total: $7.05 billion versus $6.91 billion estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +2.1% change.
- Product Sales- Oncology- Cell Therapy- Yescarta- Total: $393 million compared to the $410.81 million average estimate based on six analysts. The reported number represents a change of -5.1% year over year.
- Product Sales- Oncology- Trodelvy- Total: $364 million versus $324.16 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +13.8% change.
- Product Sales- Oncology- Cell Therapy- Tecartus- Total: $92 million compared to the $92.76 million average estimate based on six analysts. The reported number represents a change of -14% year over year.
- Product Sales- Veklury- Total: $121 million versus the six-analyst average estimate of $211.34 million. The reported number represents a year-over-year change of -43.5%.
- Product Sales- HIV- Biktarvy- Total: $3.53 billion compared to the $3.37 billion average estimate based on six analysts. The reported number represents a change of +9.2% year over year.
- Product Sales- HIV- Odefsey- Total: $298 million compared to the $287.84 million average estimate based on six analysts. The reported number represents a change of -5.4% year over year.
View all Key Company Metrics for Gilead here>>>
Shares of Gilead have returned -2.6% over the past month versus the Zacks S&P 500 composite's +1.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Gilead Sciences, Inc. (GILD): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
